Skip to main content

Kintz Samuel's Form 4 filing

Enliven Therapeutics, Inc. (ELVN) · filed Jul 29, 2024

Accession no.
0001415889-24-020265
Filed
Jul 29, 2024
Trade date
Jul 25, 2024
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions. Open-market sales total $299.1K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Kintz SamuelCIK 0001967168Director, Officer (PRESIDENT AND CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 25, 2024Common StockSSaleDisposed−3,793$24.53F2−$93,042.291,071,732Indirect
Jul 25, 2024Common StockSSaleDisposed−8,164$25.10F4−$204,916.41,063,568Indirect
Jul 25, 2024Common StockSSaleDisposed−43$25.83F5−$1,110.691,063,525Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $23.81 to $24.8005. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F4

This transaction was executed in multiple trades at prices ranging from $24.81 to $25.7811. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F5

This transaction was executed in multiple trades at prices ranging from $25.8172 to $25.8413. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)